Cannabis Weekly Round-Up: TMX Shares Update on Doing Business in the US
The Investing News rounds some of the biggest news in the cannabis market for the past trading week
Your trusted source for investing success
Your trusted source for investing success
The Investing News rounds some of the biggest news in the cannabis market for the past trading week
The Investing News rounds some of the biggest news in the cannabis market for the past trading week
Aeolus Pharmaceuticals shared the publication of a study in a peer-reviewed journal demonstrating that AEOL 10150 improves survival and protects against brain damage and oxidative stress caused by seizures after pilocarpine exposure.
The Investing News rounds some of the biggest news in the cannabis market for the past trading week
By Shelly Kumar
RespireRx Pharmaceuticals Inc. (OTCQB:RSPI) (“RespireRx” or the “Company”), a leader in the development of medicines for the treatment of respiratory disorders, including sleep apnea, opioid-induced respiratory depression, and respiratory insufficiency due to spinal cord injury, announces that the Company’s Chief Executive Officer and Vice Chairman of the Board of Directors, James
The Investing News reported took a closer look at some of the big cannabis news of the week and published an interview with the president of Cannabis Wheaton.
CURE Pharmaceutical announced its subsidiary Oak Therapeutics completed a milestone as part of their research contract with the National Institutes of Health and National Institute of Allergy and Infectious Diseases to develop 300mg of Isoniazid in a rapidly dissolving Oral Dissolvable Strip as an antituberculosis treatment.
This past trading in the cannabis marketplace saw another major dip to the Marijuana Life Sciences Index, the first medical marijuana study funded by a US medical government research group.
CorMedix secured a research grant from the National Institutes of Health to expand the Company’s antimicrobial hydrogel medical device program.
Friday Night Inc. (the “Company”) (CSE:TGIF) (FRANKFURT:1QF) is pleased to announce that the Company has appointed Dr. Anthony R. Torres, MD to its board of advisors and would also like to provide an update on the genetics breeding program at the Company’s 91% owned subsidiary, Alternative Medicine Association, LC. (AMA).
NEW
Opiant Pharmaceuticals shared a set of results from its Phase 1 trial of OPNT002.
RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), a leader in the development of medicines for the treatment of respiratory disorders for which there are no approved pharmaceuticals, particularly sleep apneas and respiratory depression resulting from pain management medicines and disabilities such as spinal cord injury, announces that the
BioCorRx revealed a partnership with the Virtual Reality Medical Center to go forward with a study on the company’s recovery program and their naltrexone implant.
Inovio Pharmaceuticals announced its HIV vaccine produced a high immune response rate in human studies.
The pharmaceutical market is only expected to increase in value in the coming years, meaning that there are exciting opportunities for investing in pharmaceutical stocks.
GeoVax Labs released their financial results for the first quarter of 2017 and gave updates on the state of its various vaccines.
A look at the types of genetic testing available to individuals.
Lion Biotechnologies will partner with The University of Texas MD Anderson Cancer Center involving various cancer clinical trials.
Trump has introduced new ways to reduce funding for medical research twice–is it possible a cure for cancer will be found under his presidency?
The President is asking congress to cut over a billion from medical research.
